GRRMF(GRRMF)

$32.20—Stale · unknown oldEarnings in 6d

Ask SA Chart

GRRMF(GRRMF)

OTC • Last print unknown ago

$32.20—Stale · unknown oldEarnings in 6d

Ask SA Chart Studio

GRRMF(GRRMF)

GRRMF

9/16/26

Gerresheimer (GRRMF)

Wednesday

10:39 AM

ThesisRecent contract wins and increased demand for specialized packaging solutions are shifting investor sentiment positively, despite ongoing margin pressures.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$2.3B	$2.3B	$2.3B
Rev. Growth	+14.0%	+0.9%	+0.3%
EPS	$-9.27	$1.82	$2.67
EPS Growth	-392%	+120%	+46.7%
P/E (fwd)	—	17.7×	12.1×

★ Analysts see FY2026 revenue reaching $2.3B — +0.9% growth in a single year.

What’s Driving the Stock

01Recent contract win with a major pharmaceutical company for a new drug delivery system expected to generate $50M in annual revenue.
02Increased demand for sustainable packaging solutions, with a projected 15% growth in this segment over the next two years.
03Potential regulatory changes in the EU that could favor Gerresheimer's advanced packaging technologies over competitors.
04Sustainability in packaging solutions
05Growth in biologics and biosimilars
06Changes in pharmaceutical production volumes, particularly in Europe and North America
07Regulatory changes impacting drug packaging standards
08Emerging trends in biologics and biosimilars requiring specialized packaging solutions

FY2025 Snapshot

Revenue: $2.3B
Rev. Growth: +14.0%
Gross Margin: 23.6%
Op. Margin: -9.0%
Net Margin: -13.8%
Net Income: $-320M
NI Growth: -392%
EPS: $-9.27
1Y Return: -37.4%

GRRMF Chart

My Notes

"We are seeing a strong uptick in demand for our innovative packaging solutions."
Moat: Gerresheimer's competitive advantage lies in its advanced manufacturing capabilities and strong relationships with major pharmaceutical…
value - Investors may find the low Price/Sales and Price/Book ratios attractive, despite recent performance challenges.
Rising interest rates may increase financing costs for capital expenditures, impacting profitability and valuation multiples.
Watch on earnings: Pharmaceutical production growth rates, Gross margin percentage, Operating cash flow trends.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $2.3B to $2.3B as recent contract win with a major pharmaceutical company for a new drug delivery system expected to generate $50m.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

—

17.7×

12.1×

What’s Driving the Stock

01Recent contract win with a major pharmaceutical company for a new drug delivery system expected to generate $50M in annual revenue.

02Increased demand for sustainable packaging solutions, with a projected 15% growth in this segment over the next two years.

03Potential regulatory changes in the EU that could favor Gerresheimer's advanced packaging technologies over competitors.

04Sustainability in packaging solutions

05Growth in biologics and biosimilars

06Changes in pharmaceutical production volumes, particularly in Europe and North America

07Regulatory changes impacting drug packaging standards

08Emerging trends in biologics and biosimilars requiring specialized packaging solutions

My Notes

"We are seeing a strong uptick in demand for our innovative packaging solutions."

Moat: Gerresheimer's competitive advantage lies in its advanced manufacturing capabilities and strong relationships with major pharmaceutical…

value - Investors may find the low Price/Sales and Price/Book ratios attractive, despite recent performance challenges.

Rising interest rates may increase financing costs for capital expenditures, impacting profitability and valuation multiples.

Watch on earnings: Pharmaceutical production growth rates, Gross margin percentage, Operating cash flow trends.